Renovis Surgical Technologies has gained clearance from the US Food and Drug Administration (FDA) for the commercialisation of its posterior lumbar Tesera porous titanium interbody fusion systems.

The Tesera fusion systems portfolio includes implants for posterior (PLIF) or transforaminal (TLIF) approaches in straight as well as curved options.

Developed using additive manufacturing (three-dimensional printing) and the firm’s porous structure called Tesera Trabecular Technology, the systems come in different heights, widths and lengths to address various patient anatomies.

Tesera Trabecular Technology enables attachment of the bone to implant surfaces and is intended to allow biologic fixation deep into the pore structure to ensure long-term stability and strength.

The technology is made from titanium alloy and supports bone in-growth, while it matches the modulus of elasticity of cancellous bone.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Tesera Trabecular Technology enables attachment of the bone to implant surfaces and is intended to allow biologic fixation deep into the pore structure to ensure long-term stability and strength.”

With an average pore diameter of approximately 500μm, the technology is designed to allow the necessary vascularisation for sustaining living bone.

In preclinical studies, the Tesera Trabecular Technology bone plugs demonstrated new bone formation and bone remodelling in and adjacent to the porous structure without implant-associated adverse effects on the host bone.

Founded in 2009, Renovis Surgical makes implants for application in orthopaedics, spine, and trauma.

In addition to the posterior lumbar systems, the FDA previously cleared the firm’s Tesera SA anterior spinal fusion system in 2013, Tesera acetabular total hip reconstruction system in 2014, first-generation Tesera posterior lumbar interbody range in 2015, and Tesera SC anterior cervical fusion system last year.


Image: Tesera Interbody family. Photo: courtesy of PRNewsfoto/Renovis Surgical Technologies.